Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 10;6(4):181877. doi: 10.1098/rsos.181877

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original author and source are credited.

PMC Copyright notice

Figure 5. — Chondrocyte cytocompatibility assay. (a) Control group. (b) PLGA fibrous scaffold. (c) 0.01% icariin group. (d) 0.1% icariin group. (e) 1% icariin group (the actual drug concentration is 0.3%). (f) 0.01% icariin + PLGA fibrous scaffold. (g) 0.1% icariin + PLGA fibrous scaffold. (h) 1% icariin + PLGA fibrous scaffold. Compared to the blank control, icariin could promote the cytocompatibility of chondrocytes (p < 0.05). With the increase in the concentration, the promotion ability rose and then fell. Compared to pristine PLGA, PLGA/icariin scaffolds could promote the proliferation of chondrocytes (p > 0.05). There were no significant differences among the three icariin concentrations (p > 0.05), *p < 0.05.